Sunder Sims-Lucas

Sunder Sims-Lucas

Auto-generated profile, based on publicly available information

Sunder Sims-Lucas

Department of Pediatrics, University of Pittsburgh Medical Center Children's Hospital of Pittsburgh (UPMC CHP), University of Pittsburgh

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Stem Cells
Verified
Journal Article
Open access
PDF file
JMJonathan L. McQualter
Jonathan L. McQualter
NBNathalie Brouard
Nathalie Brouard
BWBrenda Williams
Brenda Williams
BBBrandi N. Baird
Brandi N. Baird
SSSunder Sims-Lucas
Sunder Sims-Lucas
IBIvan Bertoncello
Ivan Bertoncello
Originally identified as a marker specifying murine hematopoietic stem cells, the Sca-1 antigen has since been shown to be differentially expressed by candidate stem cells in tissues including vascular endothelium, skeletal muscle, mammary gland, and prostate of adult mice. In the adult murine lung, Sca-1 has previously been identified as a selectable marker for the isolation of candidate nonhematopoietic (CD45−), nonendothelial (CD31−) bronchioalveolar stem cells (BASC) located at the bronchioalveolar duct junction that coexpress surfactant protein C and the Clara cell specific protein. Our systematic analysis of CD45−CD31−Sca-1+ cells in fetal, neonatal, and adult lung shows that very few of these cells are detectable prior to birth but expand exponentially postnatally coinciding with the transition from the saccular to the alveolar stage of lung development. Unlike candidate BASCs, the CD45−CD31−Sca-1+CD34+ cell fraction we describe coexpresses immunophenotypic markers (Thy-1 and platelet-derived growth factor receptor α) that define lung fibroblastic rather than epithelial cells. The mesenchymal “signature” of the CD45−CD31−Sca-1+CD34+ cell fraction is further confirmed by transcriptional profiling, by cell culture studies demonstrating enrichment for clonogenic lipofibroblastic and nonlipofibroblastic progenitors, and by immunohistochemical localization of Sca-1 in perivascular cells of the lung parenchyma. Although the CD45−CD31−Sca-1+CD34+ cell phenotype does define endogenous clonogenic progenitor cells in the adult murine lung, our data indicate that these progenitors are predominantly representative of mesenchymal cell lineages, and highlights the pressing need for the identification of alternative markers and robust functional assays for the identification and characterization of epithelial and fibroblastic stem and progenitor cell populations in the adult lung.

1 October 2019 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
TCTakuto Chiba
Takuto Chiba
KPKevin D. Peasley
Kevin D. Peasley
KCKasey R. Cargill
Kasey R. Cargill
KMKatherine V. Maringer
Katherine V. Maringer
SBSivakama S. Bharathi
Sivakama S. Bharathi
SSSunder Sims-Lucas
Sunder Sims-Lucas
Significance Statement: Proximal tubular epithelial cells, a primary site of injury in AKI, are rich in mitochondria and peroxisomes, the two organelles that mediate fatty acid oxidation. Deletion of Sirtuin 5 (Sirt5) reverses posttranslational lysine acylation of several enzymes involved in fatty acid oxidation. The authors demonstrate that mice lacking Sirt5 had significantly improved kidney function and less tissue damage following either ischemia-induced or cisplatin-induced AKI compared with wild-type mice. These differences coincided with higher peroxisomal fatty acid oxidation compared with mitochondria fatty acid oxidation in the Sirt5-deficient proximal tubular epithelial cells. Their findings indicate that Sirt5 regulates the balance of mitochondrial versus peroxisomal fatty acid oxidation in proximal tubular epithelial cells to protect against injury in AKI. This novel mechanism has potential therapeutic implications for treating AKI. Background: The primary site of damage during AKI, proximal tubular epithelial cells, are highly metabolically active, relying on fatty acids to meet their energy demands. These cells are rich in mitochondria and peroxisomes, the two organelles that mediate fatty acid oxidation. Emerging evidence shows that both fatty acid pathways are regulated by reversible posttranslational modifications, particularly by lysine acylation. Sirtuin 5 (Sirt5), which localizes to both mitochondria and peroxisomes, reverses post-translational lysine acylation on several enzymes involved in fatty acid oxidation. However, the role of the Sirt5 in regulating kidney energy metabolism has yet to be determined. Methods: We subjected male Sirt5-deficient mice (either +/− or −/−) and wild-type controls, as well as isolated proximal tubule cells, to two different AKI models (ischemia-induced or cisplatin-induced AKI). We assessed kidney function and injury with standard techniques and measured fatty acid oxidation by the catabolism of 14C-labeled palmitate to 14CO2. Results: Sirt5 was highly expressed in proximal tubular epithelial cells. At baseline, Sirt5 knockout (Sirt5−/− ) mice had modestly decreased mitochondrial function but significantly increased fatty acid oxidation, which was localized to the peroxisome. Although no overt kidney phenotype was observed in Sirt5−/− mice, Sirt5−/− mice had significantly improved kidney function and less tissue damage compared with controls after either ischemia-induced or cisplatin-induced AKI. This coincided with higher peroxisomal fatty acid oxidation compared with mitochondria fatty acid oxidation in the Sirt5−/− proximal tubular epithelial cells. Conclusions: Our findings indicate that Sirt5 regulates the balance of mitochondrial versus peroxisomal fatty acid oxidation in proximal tubular epithelial cells to protect against injury in AKI. This novel mechanism might be leveraged for developing AKI therapies.

21 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JGJ. Anthony Graves
J. Anthony Graves
YWYudong Wang
Yudong Wang
SSSunder Sims-Lucas
Sunder Sims-Lucas
ECEdward Cherok
Edward Cherok
KRKristi Rothermund
Kristi Rothermund
EPEdward V. Prochownik
Edward V. Prochownik
Although the c-Myc (Myc) oncoprotein controls mitochondrial biogenesis and multiple enzymes involved in oxidative phosphorylation (OXPHOS), the coordination of these events and the mechanistic underpinnings of their regulation remain largely unexplored. We show here that re-expression of Myc in myc−/− fibroblasts is accompanied by a gradual accumulation of mitochondrial biomass and by increases in membrane polarization and mitochondrial fusion. A correction of OXPHOS deficiency is also seen, although structural abnormalities in electron transport chain complexes (ETC) are not entirely normalized. Conversely, the down-regulation of Myc leads to a gradual decrease in mitochondrial mass and a more rapid loss of fusion and membrane potential. Increases in the levels of proteins specifically involved in mitochondrial fission and fusion support the idea that Myc affects mitochondrial mass by influencing both of these processes, albeit favoring the latter. The ETC defects that persist following Myc restoration may represent metabolic adaptations, as mitochondrial function is re-directed away from producing ATP to providing a source of metabolic precursors demanded by the transformed cell.

1 April 2013 in Kidney International
Verified
Journal Article
Closed access
PDF file
JSJohn David Spencer
John David Spencer
ASAndrew L. Schwaderer
Andrew L. Schwaderer
HWHuanyu Wang
Huanyu Wang
JBJulianne Bartz
Julianne Bartz
JKJennifer Kline
Jennifer Kline
DHDavid S. Hains
David S. Hains

18 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSSunder Sims-Lucas
Sunder Sims-Lucas
CSCaitlin Schaefer
Caitlin Schaefer
DBDaniel Bushnell
Daniel Bushnell
JHJacqueline Ho
Jacqueline Ho
ALAlison Logar
Alison Logar
CBCarlton M. Bates
Carlton M. Bates
The renal endothelium has been debated as arising from resident hemangioblast precursors that transdifferentiate from the nephrogenic mesenchyme (vasculogenesis) and/or from invading vessels (angiogenesis). While the Foxd1-positive renal cortical stroma has been shown to differentiate into cells that support the vasculature in the kidney (including vascular smooth muscle and pericytes) it has not been considered as a source of endothelial cell progenitors. In addition, it is unclear if Foxd1-positive mesenchymal cells in other organs such as the lung have the potential to form endothelium. This study examines the potential for Foxd1-positive cells of the kidney and lung to give rise to endothelial progenitors. We utilized immunofluorescence (IF) and fluorescence-activated cell sorting (FACS) to co-label Foxd1-expressing cells (including permanently lineage-tagged cells) with endothelial markers in embryonic and postnatal mice. We also cultured FACsorted Foxd1-positive cells, performed in vitro endothelial cell tubulogenesis assays and examined for endocytosis of acetylated low-density lipoprotein (Ac-LDL), a functional assay for endothelial cells. Immunofluorescence and FACS revealed that a subset of Foxd1-positive cells from kidney and lung co-expressed endothelial cell markers throughout embryogenesis. In vitro, cultured embryonic Foxd1-positive cells were able to differentiate into tubular networks that expressed endothelial cell markers and were able to endocytose Ac-LDL. IF and FACS in both the kidney and lung revealed that lineage-tagged Foxd1-positive cells gave rise to a significant portion of the endothelium in postnatal mice. In the kidney, the stromal-derived cells gave rise to a portion of the peritubular capillary endothelium, but not of the glomerular or large vessel endothelium. These findings reveal the heterogeneity of endothelial cell lineages; moreover, Foxd1-positive mesenchymal cells of the developing kidney and lung are a source of endothelial progenitors that are likely critical to patterning the vasculature.

1 March 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CGCsaba Galambos
Csaba Galambos
SSSunder Sims-Lucas
Sunder Sims-Lucas
SASteven Abman
Steven Abman
CCCarlyne D. Cool
Carlyne D. Cool